AKOS B018304
目录号 : GC30756
AKOS B018304, an arylalkylidene derivative with polar substitution at para-position, is a potent inhibitor of chikungunya virus with low micro molar activity.
Cas No.:6308-22-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
AKOS B018304, an arylalkylidene derivative with polar substitution at para-position, is a potent inhibitor of chikungunya virus with low micro molar activity.
[1] Surender Singh Jadav, et al. Eur J Med Chem. 2015 Jan 7;89:172-8.
| Cas No. | 6308-22-1 | SDF | |
| Canonical SMILES | O=C1NC(S/C1=C/C2=CC=CC=C2[N+]([O-])=O)=S | ||
| 分子式 | C10H6N2O3S2 | 分子量 | 266.3 |
| 溶解度 | DMSO : ≥ 77.5 mg/mL (291.03 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7552 mL | 18.7758 mL | 37.5516 mL |
| 5 mM | 0.751 mL | 3.7552 mL | 7.5103 mL |
| 10 mM | 0.3755 mL | 1.8776 mL | 3.7552 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Long-term renal outcomes in patients with traumatic renal injury after nephrectomy: A nationwide cohort study
Int J Surg.2019 May;65:140-146.PMID:30974184DOI: 10.1016/j.ijsu.2019.04.001.
Background: The long-term renal outcomes of patients who underwent nephrectomy for traumatic renal injury (TRI) have rarely been reported. Therefore, we investigated the impact of nephrectomy for TRI on long-term renal outcomes. Methods and materials: We extracted data from the National Health Insurance Research Database (NHIRD) of Taiwan from 1999 to 2013 and identified patients with TRI. Adverse kidney outcomes (AKOs), including lifelong dialysis and chronic kidney disease (CKD), were chosen as endpoints of the study. Results: A total of 16,320 eligible patients were identified in the NHIRD. The incidence of lifelong dialysis was 0.6% (99/15,789) for patients without nephrectomy, while the incidence was 1.1% (6/531) for nephrectomized patients. Overall, the incidence of AKOs was 2.1% (11/531) in the group that underwent nephrectomy and 1.1% (166/15,789) in the group without nephrectomy. Before matching, differences in overall AKO incidence between the groups were significant, while propensity score matching eliminated this significance. Conclusions: The results of our study did not indicate that AKOs would occur in patients with TRI who underwent nephrectomy.
Assessing parents' willingness to pursue treatment for children with attention-deficit hyperactivity disorder
J Am Acad Child Adolesc Psychiatry.1993 Jan;32(1):175-81.PMID:8428869DOI: 10.1097/00004583-199301000-00025.
Objective: This study investigated parents' willingness to pursue treatment for attention-deficit-hyperactivity-disorder (ADHD). Method: A self-administered questionnaire (the ADHD Knowledge and Opinion Scale--AKOS) was developed and administered to a sample of 116 families attending an outpatient ADHD clinic. Socioeconomic status, parenting stress, family adaptability and cohesion, degree of child's externalizing behavior, and treatment history were obtained for each family. Results: Parents' willingness to use medication or to pursue counseling were not related to family factors. History of the child receiving medication was mildly correlated with willingness to use medication. History of counseling was mildly correlated with willingness to use medication and to pursue counseling. Mothers who viewed their family as "enmeshed" reported significantly higher sense of competence than those viewing the family as "connected" or "disengaged." Conclusion: The AKOS is an instrument that may help clinicians identify and address parents' concerns about treatment for ADHD as well as parents' perceptions about their parenting skills.
Parent acceptability and feasibility of ADHD interventions: assessment, correlates, and predictive validity
J Pediatr Psychol.1996 Oct;21(5):643-57.PMID:8936894DOI: 10.1093/jpepsy/21.5.643.
Examined variables related to parents' stated willingness to pursue treatment, and their actual adherence to treatment recommendations, for children with attention deficit-hyperactivity disorder (ADHD). Parents (87 mothers; 63 fathers) of 91 patients seen for evaluation at an outpatient ADHD clinic completed the ADHD Knowledge and Opinions Survey-Revised (AKOS-R). A factor analysis of the AKOS-R revealed three relevant factors: Counseling Acceptability, Medication Acceptability, and Counseling Feasibility. Externalizing problems were positively related to parents' Counseling Acceptability ratings, while parents' ADHD knowledge was positively related to their Medication Acceptability ratings. However, Counseling Acceptability, Counseling Feasibility, and Medication Acceptability scores at intake failed to predict parents' pursual of recommended counseling and medication at follow-up. Association between treatment acceptability and adherence might be enhanced by assessing treatment acceptability at multiple points during the assessment and treatment process.
Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial
Can J Psychiatry.1999 Dec;44(10):1043-8.PMID:10637684DOI: 10.1177/070674379904401011.
Objective: This study examines the relationship between parents' knowledge of attention-deficit hyperactivity disorder (ADHD) and opinions of treatment and their impact on enrolment in and adherence to both pharmacological and nonpharmacological interventions for children with ADHD. Method: Participants in the study were the parents of 81 children who reached diagnostic criteria for ADHD and who were referred to a treatment study of ADHD involving stimulant medication and parent groups. The mothers completed a modified version of the ADHD Knowledge and Opinion Scale (AKOS) prior to receiving diagnostic feedback and prior to the families' decisions to participate in a 12-month randomized trial (medication [methylphenidate or placebo] and parent groups [training or support]). Treatment enrolment and adherence were monitored over the 12-month trial, and families who remained in the study at 12 months completed another modified AKOS. Results: A higher level of knowledge of ADHD was found to be related to more favourable opinions of parent groups but not of medication. Moreover, parents who were more knowledgeable about ADHD were more likely to enroll in both pharmacological and nonpharmacological treatments. Adherence to pharmacological and nonpharmacological treatments was not predicted by parental knowledge of ADHD or opinions of the treatment. Conclusion: Parents' knowledge of ADHD and opinions of treatments play a significant role in enrollment in treatments for their children with ADHD. Providing information to parents regarding ADHD prior to offering treatment modalities could have a favourable impact on treatment enrollment and hence treatment adherence.